N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
The present invention relates to compounds of formula I: in which p, q, Y 1 , Y 2 , R 1 , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 7 and R 8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
1. A method of treating a patient having a disease or disorder associated with receptor tyrosine kinase (RTK) alterations wherein SHP2 acts as a positive regulator, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of formula I:
wherein:
p is selected from 0 and 1;
q is selected from 0 and 1;
Y 1 is N;
Y 2 is CR 6 ;
R 1 is —XR 1a ; wherein R 1a is selected from C 6-10 aryl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl and a 5-9 member heteroaryl group containing from 1 to 4 heteroatoms or groups independently selected from N, C(O), O and S; wherein said aryl or heteroaryl of R 1a is substituted with 1 to 5 R 9 groups each independently selected from halo, amino, hydroxy, N 3 , C 1-4 alkoxy, C 1-4 alkyl, dimethyl-amino, hydroxy-substituted-C 1-4 alkyl, halo-substituted-C 1-4 alkyl, amino-substituted-C 1-4 alkyl, —C(O)OR 10 , —C(O)NH 2 , and —NHC(O)R 10 ; wherein R 10 is selected from hydrogen, phenyl, and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy; and X is selected from a bond, S(O) m , O, C(O), CR 10a R 10b , NR 11 ; wherein m is selected from 0, 1 and 2; each R 10a and R 10b is independently selected from halo and C 1-4 alkyl; and R 11 is selected from hydrogen and C 1-4 alkyl;
R 2a and R 2b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 3a and R 3b are independently selected from hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 4a and R 4b are independently selected from hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 5a and R 5b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 6 is selected from hydrogen, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, halo-substituted C 1-4 alkyl, halo-substituted C 1-4 alkoxy, hydroxy-substituted C 1-4 alkyl, amino-substituted C 1-4 alkyl, —S(O) 1-2 R 6a , —C(S)R 6a , —C(O)NR 6a R 6b , —C(NH)NR 6a R 6b and —NR 6a C(O)R 6b ; wherein R 6a and R 6b are independently selected from hydrogen and C 1-4 alkyl;
R 7 and R 8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain 1 to 3 heteroatoms or groups independently selected from N, C(O), O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 can be unsubstituted or substituted with 1 to 3 groups independently selected from amino, hydroxy, methoxy, halo, methyl, amino-methyl, methyl-amino and isobutyryloxy; or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound has a structure according to Formula Ia:
wherein:
n is selected from 1, 2, and 3;
p is selected from 0 and 1;
q is selected from 0 and 1;
Y 1 is N;
Y 2 is CR 6 ;
Y 4 is independently selected from N and CR 9 ;
R 6 is selected from hydrogen, halo, and methyl;
R 7 and R 8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain a heteroatom or group selected from N, C(O), O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 can be unsubstituted or substituted with 1 to 3 groups independently selected from amino, halo, hydroxy, methyl, methoxy, amino-methyl, methyl-amino, and isobutyryloxy;
R 9 is selected from halo, amino, hydroxy, N 3 , dimethyl-amino, C 1-4 alkyl, halo-substituted-C 1-4 alkyl, C 1-4 alkoxy, —C(O)OR 10 , —C(O)NH 2 , and —NHC(O)R 10 ;
R 10 is selected from hydrogen, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy; or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein R 7 and R 8 together with the carbon atom to which they are both attached form a 5 member saturated or partially unsaturated ring that can optionally contain 1 to 2 heteroatoms or groups independently selected from N, O, C(O) and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with 1 to 3 groups independently selected from amino, hydroxy, methoxy, halo, methyl, methyl-amino and isobutyryloxy.
4. The method of claim 3 , wherein the compound, or the pharmaceutically acceptable salt thereof, is selected from:
5. The method of claim 2 , wherein R 7 and R 8 together with the carbon atom to which they are both attached form a 6 member saturated or partially unsaturated ring that can optionally contain a heteroatom or group selected from N, O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with amino.
6. The method of claim 5 , wherein the compound, or the pharmaceutically acceptable salt thereof, is:
7. The method of claim 2 , wherein R 7 and R 8 together with the carbon atom to which they are both attached form a 4 member saturated or partially unsaturated ring that can optionally contain a heteroatom or group selected from N, O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 is substituted with a group selected from amino, amino-methyl and methyl-amino.
8. The method of claim 7 , wherein the compound, or the pharmaceutically acceptable salt thereof, is selected from:
9. The method of claim 2 , wherein the compound, or the pharmaceutically acceptable salt thereof, is selected from:
10. The method of claim 1 , wherein the compound has a structure according to formula II:
wherein:
p is selected from 0 and 1;
q is selected from 0 and 1;
Y 1 is N;
Y 2 is CR 6 ;
R 1 is —XR 1a ; wherein X is a bond and Ria is selected from C 6-10 aryl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl and a 5-9 member heteroaryl group containing from 1 to 4 heteroatoms selected from N, O and S; wherein said aryl or heteroaryl of R 1a is substituted with 1 to 5 R 9 groups independently selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, hydroxy-substituted-C 1-4 alkyl, halo-substituted-C 1-4 alkyl, amino-substituted-C 1-4 alkyl, —C(O)OR 10 and —NHC(O)R 10 ; wherein R 10 is selected from hydrogen, phenyl, and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy;
R 2a and R 2b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 3a and R 3b are independently selected from hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 4a and R 4b are independently selected from hydrogen, halo, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 5a and R 5b are independently selected from hydrogen, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl and C 1-4 alkyl-amino;
R 6 is selected from hydrogen, halo, cyano, C 1-4 alkyl, C 1-4 alkoxy, halo-substituted C 1-4 alkyl, halo-substituted C 1-4 alkoxy, hydroxy-substituted C 1-4 alkyl and amino-substituted C 1-4 alkyl;
R 7 and R 8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain a heteroatom or group selected from N, O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 can be unsubstituted or substituted with 1 to 3 groups independently selected from amino, halo, hydroxy, amino-methyl and methyl-amino; or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 , wherein the compound has a structure according to Formula IIa:
in which:
n is selected from 1, 2, 3 and 4;
p is selected from 0 and 1;
q is selected from 0 and 1;
Y 1 is N;
Y 2 is CR 6 ;
Y 4 is selected from N and CR 9 ;
R 6 is selected from hydrogen, halo, and methyl;
R 7 and R 8 together with the carbon atom to which they are both attached form a 3 to 7 member saturated or partially unsaturated ring that can optionally contain a heteroatom or group selected from N, O and S(O) m ; wherein m is selected from 0, 1 and 2; wherein said saturated ring formed by R 7 and R 8 can be unsubstituted or substituted with a group selected from amino, amino-methyl and methyl-amino;
R 9 is selected from halo, amino, hydroxy, N 3 , C 1-4 alkyl, halo-substituted-C 1-4 alkyl, —C(O)OR 10 and —NHC(O)R 10 ;
R 10 is selected from hydrogen, phenyl and naphthyl; wherein said phenyl of R 10 is unsubstituted or substituted with methoxy; or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 , wherein the compound, or a pharmaceutically acceptable salt thereof, is selected from:
13. The method of claim 10 , wherein the compound, or a pharmaceutically acceptable salt thereof, is:
14. The method of claim 10 , wherein the compound, or a pharmaceutically acceptable salt thereof, is selected from:
15. The method of claim 10 , wherein the compound, or the pharmaceutically acceptable salt thereof, is:
16. The method of claim 1 wherein the RTK alterations are selected from amplifications of EGFR, Her2, FGFR and Met.
17. The method of claim 1 wherein the RTK alterations are translocated or activated receptor tyrosine kinases.
18. The method of claim 17 wherein the translocated or activated receptor tyrosine kinases are selected from ALK and BCR-ABL.
19. The method of claim 1 wherein the disease or disorder is selected from esophageal cancer, breast cancer, lung cancer, colon cancer, gastric cancer, glioma, neuroblastoma, and head and neck cancer.
20. The method of claim 19 wherein the breast cancer is selected from luminal A, luminal B, Her2 and triple negative breast cancer.
21. The method of claim 19 wherein the lung cancer is non-small cell lung cancer.
22. The method of claim 19 wherein the colon cancer is characterized by colorectal tumors with mutated KRAS.
23. The method of claim 19 wherein the colon cancer is characterized by mutated BRAF.
24. The method of claim 19 wherein the head and neck cancer is squamous-cell carcinoma of the head and neck.
25. The method of claim 4 , wherein the compound, or the pharmaceutically acceptable salt thereof, is:
26. The method of claim 1 , wherein the disease or disorder is a cancer containing RTK alterations wherein SHP2 acts as a positive regulator.